CTOs on the Move

Minneola District Hospital

www.mdh2.org

 
Minneola District Hospital is a Minneola, KS-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.mdh2.org
  • PO BOX 127
    Minneola, KS USA 67865
  • Phone: 620.885.4264

Executives

Name Title Contact Details

Similar Companies

Volk Optical Inc

Volk Optical Inc is a Mentor, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Gynesonics

At Gynesonics our mission is to design and develop new and advanced technologies for improving women`s health. We are focused on providing an incision-free option to women and the physicians who care for them, in treating symptomatic uterine fibroids. We are initiating a pivotal IDE trial in the United States to verify the safety and efficacy of the Sonata system, in preserving the uterus while treating those fibroids associated with abnormal uterine bleeding that are difficult to treat with existing technology and surgical techniques. We are committed to providing women with a safe and effective incision-free alternative to the invasive surgical techniques of hysterectomy or myomectomy for their severe menstrual symptoms associated with fibroids.

Mada Medical Products

Mada is a manufacturer of several hundred Medical, Dental, Podiatric and Veterinary products catering to the Home Healthcare and Institutional markets. Mada was incorporated in 1969, with Production and Corporate Offices located in Carlstadt, New Jersey

Ortonville Area Health Services

Ortonville Area Health Services is a healthcare system that includes Ortonville Hospital, Northridge Residence (nursing home), Northside Medical Clinic, Clinton Clinic, and OAHS Home Health Agency. They offer a broad scope of services to keep you and y...

scPharmaceuticals

scPharmaceuticals, based in Lexington, MA, is a privately held biopharmaceutical company developing a portfolio of transformative pharmaceutical products for subcutaneous delivery. Based on widely used generic drugs that currently require intravenous or intramuscular injections, our innovative products will be administered subcutaneously via a proprietary patch pump. This avoids material risks and costs associated with the current delivery options. Our lead products are the first subcutaneous formulations of furosemide (the most widely used parenteral diuretic in treating heart failure) and ceftriaxone (the most widely used parenteral antibiotic outside the hospital setting). Our novel furosemide formulation enables convenient anytime anywhere use, for example in an outpatient setting instead of the emergency room or other in-patient settings. For ceftriaxone and other antibiotics, subcutaneous administration eliminates the need for PICCs (peripherally inserted central catheters), which are associated with serious complications, frequent adverse events and high medical cost. For further information on how we are transforming the administration of parenteral drugs.